We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
Read MoreHide Full Article
Key Takeaways
Axsome's lead drug Auvelity has been the primary driver of top-line growth since its U.S. launch.
Auvelity posted $352M in sales in the first nine months of 2025, which increased 77% year over year.
Axsome's sNDA for AXS-05 in Alzheimer's disease agitation has an FDA decision set for April 2026.
Axsome Therapeutics (AXSM - Free Report) has been witnessing a strong sales uptake for its lead marketed drug, Auvelity (AXS-05), which is approved for treating major depressive disorder. Since its launch in the United States in 2022, the drug has played an instrumental role in driving the company’s top line.
Auvelity recorded sales worth $352 million in the first nine months of 2025, reflecting an increase of 77% on a year-over-year basis, driven by an increase in unit sales volume. Axsome recently reported preliminary results for the fourth quarter and full-year 2025.
The company expects total product revenues to be approximately $196 million for the fourth quarter and around $638.5 million for the full year, reflecting a year-over-year increase of 65% and 66%, respectively. Axsome’s product revenues comprise sales of its marketed drugs, Auvelity, Sunosi (solriamfetol) and the newest drug, Symbravo (meloxicam and rizatriptan).
Auvelity’s net product sales are expected to be around $155.1 million and $507.1 million for the fourth quarter and full-year 2025, respectively. The drug is also being developed in several label expansion studies for other central nervous system (CNS) disorders like Alzheimer’s disease (AD), agitation and smoking cessation.
The FDA recently accepted the supplemental new drug application (“sNDA”) seeking approval for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of patients with AD agitation. With the FDA granting a priority review to the sNDA, a decision from the regulatory body is now expected on April 30, 2026.
A potential label expansion for Auvelity should help Axsome address a broader patient population and drive sales further in the future quarters.
Besides Auvelity, Axsome’s narcolepsy drug, Sunosi (solriamfetol), is also generating incremental sales and aiding the top line. Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ - Free Report) in May 2022.
In the first nine months of 2025, Sunosi sales increased 29.1% on a year-over-year basis. The acquisition of Sunosi from Jazz diversified the company’s commercial portfolio. Sunosi net product revenues are anticipated to be around $36.7 million and $124.8 million for the fourth quarter and full-year 2025, respectively.
Axsome’s newest product, Symbravo, was approved by the FDA for the acute treatment of migraine with or without aura in adults in January 2025. The drug was launched in the United States in June 2025. Symbravo net product sales are expected to be around $4.1 million and $6.6 million for the fourth quarter and full-year 2025, respectively.
The approval of Symbravo further solidified Axsome’s commercial footprint in the target market. However, competition looms large.
AXSM’s Competition in the Target Market
While Axsome is benefiting from Auvelity’s success and other commercial efforts, the competitive landscape remains challenging, with some companies developing therapies for various CNS disorders. Acadia Pharmaceuticals (ACAD - Free Report) is one such company that currently markets its lead drug, Nuplazid (pimavanserin), for a CNS disorder.
ACAD’s Nuplazid was the first and only drug approved by the FDA for hallucinations and delusions associated with Parkinson’s disease psychosis. The ACAD drug recorded sales worth $505.7 million, up 13% year over year, during the first nine months of 2025.
Sunosi is also likely to face competition from Jazz’s sleep disorder drugs, which hold a strong market share.
Meanwhile, Symbravo will likely encounter competition from established players in the migraine market, including Pfizer’s Nurtec ODT/Vydura and AbbVie’s Ubrelvy and Qulipta/Aquipta. These products are already widely prescribed and supported by a strong commercial infrastructure, which may pose adoption challenges for newer entrants. This is likely to induce acute competition for Axsome and might impact its longer-term growth trajectory.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
Key Takeaways
Axsome Therapeutics (AXSM - Free Report) has been witnessing a strong sales uptake for its lead marketed drug, Auvelity (AXS-05), which is approved for treating major depressive disorder. Since its launch in the United States in 2022, the drug has played an instrumental role in driving the company’s top line.
Auvelity recorded sales worth $352 million in the first nine months of 2025, reflecting an increase of 77% on a year-over-year basis, driven by an increase in unit sales volume. Axsome recently reported preliminary results for the fourth quarter and full-year 2025.
The company expects total product revenues to be approximately $196 million for the fourth quarter and around $638.5 million for the full year, reflecting a year-over-year increase of 65% and 66%, respectively. Axsome’s product revenues comprise sales of its marketed drugs, Auvelity, Sunosi (solriamfetol) and the newest drug, Symbravo (meloxicam and rizatriptan).
Auvelity’s net product sales are expected to be around $155.1 million and $507.1 million for the fourth quarter and full-year 2025, respectively. The drug is also being developed in several label expansion studies for other central nervous system (CNS) disorders like Alzheimer’s disease (AD), agitation and smoking cessation.
The FDA recently accepted the supplemental new drug application (“sNDA”) seeking approval for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of patients with AD agitation. With the FDA granting a priority review to the sNDA, a decision from the regulatory body is now expected on April 30, 2026.
A potential label expansion for Auvelity should help Axsome address a broader patient population and drive sales further in the future quarters.
Besides Auvelity, Axsome’s narcolepsy drug, Sunosi (solriamfetol), is also generating incremental sales and aiding the top line. Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ - Free Report) in May 2022.
In the first nine months of 2025, Sunosi sales increased 29.1% on a year-over-year basis. The acquisition of Sunosi from Jazz diversified the company’s commercial portfolio. Sunosi net product revenues are anticipated to be around $36.7 million and $124.8 million for the fourth quarter and full-year 2025, respectively.
Axsome’s newest product, Symbravo, was approved by the FDA for the acute treatment of migraine with or without aura in adults in January 2025. The drug was launched in the United States in June 2025. Symbravo net product sales are expected to be around $4.1 million and $6.6 million for the fourth quarter and full-year 2025, respectively.
The approval of Symbravo further solidified Axsome’s commercial footprint in the target market. However, competition looms large.
AXSM’s Competition in the Target Market
While Axsome is benefiting from Auvelity’s success and other commercial efforts, the competitive landscape remains challenging, with some companies developing therapies for various CNS disorders. Acadia Pharmaceuticals (ACAD - Free Report) is one such company that currently markets its lead drug, Nuplazid (pimavanserin), for a CNS disorder.
ACAD’s Nuplazid was the first and only drug approved by the FDA for hallucinations and delusions associated with Parkinson’s disease psychosis. The ACAD drug recorded sales worth $505.7 million, up 13% year over year, during the first nine months of 2025.
Sunosi is also likely to face competition from Jazz’s sleep disorder drugs, which hold a strong market share.
Meanwhile, Symbravo will likely encounter competition from established players in the migraine market, including Pfizer’s Nurtec ODT/Vydura and AbbVie’s Ubrelvy and Qulipta/Aquipta. These products are already widely prescribed and supported by a strong commercial infrastructure, which may pose adoption challenges for newer entrants. This is likely to induce acute competition for Axsome and might impact its longer-term growth trajectory.